Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Recruiting now · Phase 1
Conditions studied: Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma
In brief
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
Key facts
- Study ID
- NCT06915753
- Run by
- Tyra Biosciences, Inc
- People needed
- 100
- Starts
- 2025-04-24
- Expected to finish
- 2028-09-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
- UCSF Medical Center at Mount Zion — San Francisco, California, United States (enrolling)
- Stanford Cancer Institute — Stanford, California, United States (enrolling)
- The University of Kansas Medical Center — Westwood, Kansas, United States (enrolling)
- John Hopkins University — Baltimore, Maryland, United States (enrolling)
- Mass General Cancer Center — Boston, Massachusetts, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Columbia University Irving Medical Center — New York, New York, United States (enrolling)
- Sarah Cannon Research Institute Oncology Partners — Nashville, Tennessee, United States (enrolling)
- University Health Network Princess Margaret Cancer Center — Toronto, Ontario, Canada (enrolling)
- Asan Medical Center — Seoul, South Korea (enrolling)
- Samsung Medical Center — Seoul, South Korea (enrolling)
- Seoul National University Hospital — Seoul, South Korea (enrolling)
- Severance Hospital, Yonsei University Health System — Seoul, South Korea (enrolling)
- National Taiwan University Hospital — Taipei, Taiwan (enrolling)
- Taipei Veterans General Hospital — Taipei, Taiwan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.